
The Cerebral Valley Podcast
The Cerebral Valley AI Summit is back. So Eric, Max, and James are taking stock of where the industry is headed before our summit in London on June 25. cerebralvalleysummit.com
Show episodes
We’re officially one week out from the Cerebral Valley AI Summit! On today’s episode, co-hosts James Wilsterman and Max Child of Volley join host Eric Newcomer to preview what’s ahead — from standout speakers to can’t-miss panels and the big ideas that will shape the conversations next week. To kick things off, Eric po
In this second installment of the Cerebral Valley podcast series, co-hosts James Wilsterman and Max Child of Volley join Eric Newcomer for a thought-provoking conversation about the future of AI-generated voice and video — and what it means for our sense of reality. From TikTok trends to the future of Hollywood and pod
The Cerebral Valley AI Summit is right around the corner! To help you navigate the fast-evolving AI landscape ahead of the event, Newcomer Podcast is launching a special four-part series — co-hosted by James Wilsterman and Max Child of Volley. Get insider insights, expert analysis, and fresh perspectives on the trends
We're welcoming Bloomberg's Kate Clark to the show this week and diving into her reporting on the rough fundraising environment for any VC that isn't an a16z or GC-style megafund. The only emerging funds that can raise, it seems, are ones that are started by investors who leave these brands. If it weren't for the AI fu
In this special episode, we feature two interviews recorded live during Newcomer’s Breaking the Bank Summit, a financial technology summit held this week in San Francisco. We’re including two of the most dynamic discussions here, beginning with Gabriel Stengel of Rogo and Jeff Seibert of Digits, followed by an intervie
Eric relays his dispatch from Dimension Capital’s biotech summit in Park City, where the crowd was much more academic than the conferences we usually attend. Biotech stocks aren’t doing great, meanwhile university funding cuts could spell trouble for drug research. Still, people were rosy about AI tools. We also took